Technology | September 22, 2009

FDA Clears 2.25 mm CYPHER Sirolimus-Eluting Coronary Stent

September 22, 2009 – Cordis Corp. has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER Sirolimus-Eluting Coronary Stent – the 2.25 mm CYPHER – which is indicated for treatment of coronary blockages in small vessels.

“Small vessels can mean big challenges, and it will be very beneficial for interventionalists and their patients to now have access to a CYPHER® Stent specifically designed for these complex cases,” said John Lasala, M.D., Ph.D., professor of medicine; director, interventional cardiology and medical director, cardiac catheterization, Washington University School of Medicine in St. Louis. Dr. Lasala is affiliated with Barnes-Jewish Hospital in St. Louis. “The long-term clinical benefits of the CYPHER Stent are well documented in a broad range of patient and lesion types and this approval now allows this benefit to be applied to the treatment of small vessels.”

Many types of patients have small vessel disease, including women and those with certain other medical conditions. Small coronary vessels have been associated with an increased risk of re-blockage (restenosis) after stent implantation, which requires another procedure to reopen the vessel. The smaller the artery, the more the regrowth of cells within a stent, and stent recoil narrow the lumen. This accentuates the clinical benefits of the CYPHER Stent, which is unsurpassed in limiting this process.
Today’s approval is based on the results of four studies including, in part, the clinical results of the SES-SMART trial. This trial was a randomized comparison of the 2.25 mm CYPHER Stent to bare metal stents in the reduction of restenosis in small coronary arteries. At two years of follow up, patients receiving the CYPHER Stent had significantly better clinical outcomes than those patients receiving a bare metal stent. In fact, use of the CYPHER Stent led to an 82 percent reduction in restenosis compared to a bare metal stent at six months.

In recent months, the FDA has approved two other drug-eluting stents for the treatment of small vessel disease, the TAXUS Liberte Atom Stent and the TAXUS Express Atom Stent, both of which elute paclitaxel. The CYPHER Stent, which elutes sirolimus, has outperformed the TAXUS stent in numerous clinical trials, Cordis said. In the ISAR-SMART 3 trial, for example, patients treated with the CYPHER Stent had 55 percent less late loss after eight months than patients receiving a TAXUS. Data from the RESEARCH and T-SEARCH registries showed that patients treated with the 2.25 mm CYPHER had a 65 percent lower incidence of death or myocardial infarction (MI) than patients treated with a 2.25 mm TAXUS.

Dr. Lasala is compensated for his time as a consultant to the company and a member of the company’s scientific advisory board.

For more information: www.cypherstent.com, www.cordis.com

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init